Skip to main content

Day: December 6, 2023

Global Telehealth Market Size, Share & Growth Analysis, [2030] | With CAGR of 19.7%

As per the report by Fortune Business Insights, The global telehealth market size was valued at USD 128.12 billion in 2022. The market is projected to grow from USD 142.96 billion in 2023 to USD 504.24 billion by 2030 at a CAGR of 19.7% during the forecast period.Telehealth MarketForecast 2023-2030Pune, India, Dec. 06, 2023 (GLOBE NEWSWIRE) — Global telehealth market size was valued at USD 128.12 billion in 2022 The market is projected to grow from USD 504.24 billion by 2030 at a CAGR of 19.7% during the forecast period.The increasing adoption of telehealth is growing dramatically, especially in behavioral health, radiology, cardiology, and online consultation. The market is getting a significant boom with the growing start-up’s launch and funding of products, especially for virtual consultations. This information...

Continue reading

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 SCOTTSDALE, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company received the official meeting minutes from its pre-New Drug Application (“NDA”) meeting with the FDA for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) to treat rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories Ltd. The purpose of the meeting was to discuss the 505(b)(2) NDA submission plan...

Continue reading

Automate Installation Process with Press-Fit Terminal Power Modules for a Solder-Free Solution in High-Volume Manufacturing

Microchip’s SP1F and SP3F power modules are highly configurable in Silicon Carbide (SiC) or Silicon (Si) technology and now available with Press-Fit terminals CHANDLER, Ariz., Dec. 06, 2023 (GLOBE NEWSWIRE) — The E-Mobility, sustainability and data center markets require products that are conducive to high-volume manufacturing. To better automate the installation process, Press-Fit terminals are often used because they offer a solder-free solution to mount power modules to the PCB. Microchip Technology (Nasdaq: MCHP) today announces its expansive portfolio of SP1F and SP3F power modules are now available with Press-Fit terminals for high-volume applications. Solder-free Press-Fit power module terminals allow for automated or robotic installation, which simplifies and speeds up the assembly process to reduce manufacturing costs....

Continue reading

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly 19, 2024 PDUFA target action date assigned by the FDAFLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has accepted for review the company’s NDA for VOQUEZNA (vonoprazan) as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) in adults. The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024. “Today...

Continue reading

Gentherm Announces Laura Kowalchik as New Independent Director

NORTHVILLE, Mich., Dec. 06, 2023 (GLOBE NEWSWIRE) — Gentherm (NASDAQ: THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Laura Kowalchik has been appointed to the Company’s Board of Directors, effective December 1, 2023. Kowalchik is the Chief Financial Officer of Communications & Power Industries LLC (“CPI”), a global manufacturer of electronic components and subsystems primarily within the communications and defense markets, where she oversees the finance and accounting departments and is actively involved in strategy, M&A and restructuring activities. Prior to joining CPI, Kowalchik served as the Chief Financial Officer of Dayco Incorporated, a global manufacturer...

Continue reading

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Top-line data expected in Q2 2024SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company, along with Mundipharma, has completed enrollment in the Phase 3 ReSTORE trial in China evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis. The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current...

Continue reading

Tilray Brands Unveils Canadian Cannabis Lineup for the Holidays

From Premium Chocolate Edibles to Power Packed Drinks, Pre-rolls, and Quality Flower, Find Something Special for the Cannabis Enthusiast on Your List TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, through its wholly-owned licensed subsidiaries, Aphria Inc, and Hexo Operations Inc., and Truss Beverages Company Limited, unveils its 2023 holiday products spotlighting essentials from its diverse portfolio of brands, offering a wide range of options for consumers to explore and share during this festive time of year. For the Chocolate Edibles Connoisseur Chowie Wowie: Premium Chocolate BarsLicensed producer: Aphria Inc.Crunchy Praline: Another 1:1 of 10mg of THC and 10mg of CBD,...

Continue reading

Stryker announces Dr. Srikant Datar will retire from Board of Directors

Kalamazoo, Michigan, Dec. 06, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced today that after 15 years of distinguished service, Dr. Srikant Datar has notified the Company that he will not stand for re-election at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024. Dr. Datar is the Dean of the Harvard Business School and George F. Baker Professor of Business Administration. He was the Arthur Lowes Dickinson Professor at the Graduate School of Business Administration of Harvard University from 1996 to 2020 and is the former Faculty Chair of the Harvard Innovation Labs and Senior Associate Dean for University Affairs. From 1989 to 1996, Dr. Datar was Edmund W. Littlefield Professor at the Graduate School of Business, Stanford University. Dr. Datar is also a director of ICF International,...

Continue reading

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain. “We are pleased DUROLANE is among the preferred options available...

Continue reading

Clubhouse Media Group, Inc. Exploring Implementation Of AI on the HoneyDrip.com Platform + Announces Growth Results For November 2023

LOS ANGELES, Dec. 06, 2023 (GLOBE NEWSWIRE) — Clubhouse Media Group, Inc. (OTCMKTS: CMGR) (“CMGR”), a social media firm and digital agency, today announced that HoneyDrip.com is engaging various AI consultants to explore the potential of using AI to support the back-end functions of the site and to enhance processes. The site has also seen month over month growth, continuing into November 2023. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content. HoneyDrip.com has experienced rapid growth in four main categories during the month of November 2023 alone:       1)   Active performers on the site (by Invite Only) increased by 5%       2)   Content posts (photos and videos)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.